A NeuroMuse GmbH Technology Transfer Project

Project M.

A topical-product development project for Jordan, North Africa & the Gulf

A technology-transfer opportunity for pharmaceutical partners.

Development project for professional partners. No product sales, patient-use advice or claim of regulatory approval.
Project M topical product
0.01%Topical solution
150 mlSpray format
Jordan & North AfricaPrimary target markets

The Opportunity

A development concept. A regional partnership.

Project M explores a topical product based on a quaternary ammonium compound for Jordan, North Africa (Morocco, Algeria, Tunisia, Libya, Egypt) and the Gulf states. We seek a regional pharmaceutical partner to assess the technical evidence, confirm the appropriate regulatory classification and develop a market-specific pathway.

What we offer

01A preliminary formulation and presentation concept for technical assessment
02Formulation know-how, available technical data and an active-substance sourcing route for partner due diligence
03Coordination of a proposed local development and regulatory plan, subject to authority requirements

Development

Three development options

Options subject to evidence, classification and local authority decisions.

01

Option 1 · Care concept

Assess a care-spray concept only where its formulation, intended use and claims fit the applicable local category. No fast-track or launch date is promised.

02

Option 2 · Wound-care assessment

Explore the appropriate route for a wound-care concept. A medical-device pathway is conditional on lawful classification, including the principal mode of action, and is not assumed.

03

Option 3 · Medicine development

Evaluate a medicinal-product dossier, required studies and authorisation. Other dosage forms would need separate development and applicable approvals.

Regional Partnership

Shared expertise. Local reach.

We are looking for a strong regional pharmaceutical partner for registration, manufacturing or distribution, and marketing.

WE BRINGThe technology, the data and the project coordination.
THE PARTNER BRINGSLocal market access.
Laboratory work for Project M
Current Status
"We are open to discussions with qualified pharmaceutical partners in the region."

Start a Conversation

Let's explore a regional partnership.

Start with a non-confidential introduction. Detailed information is shared only after an agreed NDA; contacting us does not itself create confidentiality obligations. The contact link opens your email application. Please do not send health information.

Project M by NeuroMuse GmbH

A technology-transfer development project for the MENA region.
By NeuroMuse GmbH · Basel, Switzerland.

Company information

NeuroMuse GmbH · c/o Abelia Wirtschaftsprüfung und Beratung AG, Dufourstrasse 49, 4052 Basel, Switzerland · UID CHE-344.882.117. Project M is a technology-transfer development concept and not a marketed product.

Privacy notice

We process personal data in accordance with the revised Swiss Federal Act on Data Protection (revFADP) and, where applicable, the EU GDPR. We use your data only to answer your enquiry. We do not sell it. Our service providers for website hosting and email process it on our behalf. Contact ts@neuromuse-m.com for privacy requests.

Cookies & external services

This website uses only strictly necessary cookies. No tracking, analytics, or third-party advertising services are active on this site.

Professional & Project M notices

Project M is a development concept for professional pharmaceutical partners only. It does not constitute a product offer, medical advice, or a claim of regulatory approval. All development options are subject to evidence, classification, and local authority decisions. No fast-track or launch date is promised.

Website terms & accessibility

All content is provided for informational purposes only. NeuroMuse GmbH makes no warranties regarding accuracy or completeness. For accessibility assistance, contact ts@neuromuse-m.com. This site is designed to be accessible and compliant with WCAG 2.1 AA guidelines.

© 2026 NeuroMuse GmbH · UID CHE-344.882.117Last updated: 14 October 2026